Serum Sphingosine-1-phosphate level and peritonitis in peritoneal dialysis patients

Qiong Bai, Hong-Xia Guo, Chun-Yan Su, Qing-Feng Han, Tao Wang and Wen Tang
Department of Nephrology, Peking University Third Hospital, Beijing, China

ABSTRACT
Background: Given the important role of Sphingosine-1-phosphate (S1P) in maintaining the hemostasis in intestinal barrier function and regulation of inflammation and immune, we hypothesize that S1P might be a biomarker to predict peritonitis in peritoneal dialysis (PD) patients.
Methods: In this case-control study, 78 stable, continuous ambulatory peritoneal dialysis patients were enrolled and followed for the episode of PD associated peritonitis. Patients were divided into two groups by whether or not they had peritonitis during follow-up: non-peritonitis (n = 65) and peritonitis (n = 13) group. S1P was analyzed by enzyme-linked immunosorbent assay. Logistic regression analysis was used to assess factors associated with peritonitis. The variables identified by univariable regression models (p < 0.1) were further selected into the multivariable logistic regression model to determine whether they could independently affect peritonitis.
Results: Patients with peritonitis had a lower level of S1P than that of patients without peritonitis (1.3 ng/mL IQ 0.8, 3.6 ng/mL vs. 2.8 ng/mL IQ 1.5, 5.4 ng/mL, p = 0.018). The peritonitis group had lower serum albumin, lower blood leukocyte, lower hemoglobin and lower platelet count as compared to the non-peritonitis group. Logistic regression analysis showed that S1P (OR = 0.381, 95% CI = 0.171 – 0.848, p = 0.018), blood leukocyte count (OR = 0.438, 95% CI = 0.207–0.925, p = 0.030), and serum albumin (OR = 0.732, 95% CI = 0.556–0.962, p = 0.025) were independent factors associated with peritonitis in the present PD population.
Conclusion: Our study showed that S1P was an independent determinant of subsequent peritonitis in PD patients. S1P might serve as a biomarker to predict peritonitis in PD patients.

Introduction
Peritoneal dialysis (PD) is currently a renal replacement therapy (RRT) modality for the treatment of end-stage renal disease (ESRD) [1]. However, PD related peritonitis is a serious complication which is the greatest contributor to infection-related morbidity, including risk for hospitalization, and temporary or permanent transfer to hemodialysis [2–4]. Risk factors for PD related peritonitis have been well documented, with bacterial translocation from the gut well accepted as a potential cause of peritonitis [5]. In patients with liver cirrhosis, spontaneous bacterial peritonitis resulting from abnormal intestinal permeability and bacterial overgrowth have also been well documented as risk factors [6,7]. In addition for patients with renal failure, impaired gastrointestinal barrier function and increased gut permeability promote the translocation of bacteria [8–14].

In the human gut, the integrity of the epithelial cell layer, which forms an important barrier for gastrointestinal tract, strongly depends on specialized structures involved in cell-cell contacts, including tight junctions, adherent junctions, and desmosomes [15]. Sphingosine-1-phosphate (S1P) has recently shown to be a potent bioactive sphingolipid metabolite that regulates diverse cellular processes, which are important for inflammation, immune responses and barrier regulation [16–22]. Previous studies have reported that S1P protects intestinal epithelial cell from apoptosis, maintains cell-cell contacts in gut epithelial cells and ultimately plays a critical role in modulating the integrity of the intestinal barrier [23].

In the human gut, the integrity of the epithelial cell layer, which forms an important barrier for gastrointestinal tract, strongly depends on specialized structures involved in cell-cell contacts, including tight junctions, adherent junctions, and desmosomes [15]. Sphingosine-1-phosphate (S1P) has recently shown to be a potent bioactive sphingolipid metabolite that regulates diverse cellular processes, which are important for inflammation, immune responses and barrier regulation [16–22]. Previous studies have reported that S1P protects intestinal epithelial cell from apoptosis, maintains cell-cell contacts in gut epithelial cells and ultimately plays a critical role in modulating the integrity of the intestinal barrier [23].

In the human gut, the integrity of the epithelial cell layer, which forms an important barrier for gastrointestinal tract, strongly depends on specialized structures involved in cell-cell contacts, including tight junctions, adherent junctions, and desmosomes [15]. Sphingosine-1-phosphate (S1P) has recently shown to be a potent bioactive sphingolipid metabolite that regulates diverse cellular processes, which are important for inflammation, immune responses and barrier regulation [16–22]. Previous studies have reported that S1P protects intestinal epithelial cell from apoptosis, maintains cell-cell contacts in gut epithelial cells and ultimately plays a critical role in modulating the integrity of the intestinal barrier [23].

In the human gut, the integrity of the epithelial cell layer, which forms an important barrier for gastrointestinal tract, strongly depends on specialized structures involved in cell-cell contacts, including tight junctions, adherent junctions, and desmosomes [15]. Sphingosine-1-phosphate (S1P) has recently shown to be a potent bioactive sphingolipid metabolite that regulates diverse cellular processes, which are important for inflammation, immune responses and barrier regulation [16–22]. Previous studies have reported that S1P protects intestinal epithelial cell from apoptosis, maintains cell-cell contacts in gut epithelial cells and ultimately plays a critical role in modulating the integrity of the intestinal barrier [23].

Given the important role of S1P in maintaining hemostasis in gut barrier function and achieving immune regulation, we hypothesize that S1P might be a biomarker to predict peritonitis in PD patients.
Therefore, in the present study, we investigated the association of serum S1P level and risk of peritonitis in PD patients.

**Methods**

In this case-control study, patients who visited our PD clinic for routine clinic evaluation from 19 December 2016 to 20 February 2017 and had their blood tested were grouped according to whether or not they had peritonitis by the follow-up date of 31 January 2018. Seventy-eight stable, continuous ambulatory peritoneal dialysis (CAPD) patients were enrolled from our PD program. All patients received CAPD treatment with dialysate containing 132 mmol/L of sodium and 1.5 or 2.5% of glucose concentration (Dianeal, Baxter Healthcare, Guangzhou, China). In our center, dialysis policy was implemented as previously described. Gradual increases in the PD dose were prescribed while the residual kidney function no longer could maintain the fluid balance and the total Kt/V reached 1.7 if possible. Consequently, all patients received 3–5 units of exchange (2 L per exchange) per day during the follow-up.

Exclusion criteria were (1) the duration of patients treated with CAPD was less than 3 months before the inclusion period; (2) patients were age <18 years; (3) patients with overt heart failure (NYHA grade III–IV); (4) patients had autoimmune disease; (5) patients had history of malignant disease; (6) patients had history of liver cirrhosis; (7) patients had history of intestinal inflammatory disease. The study was approved by the Medical Ethical Committee of Peking University.

Clinical data, demographic data and laboratory examinations were prospectively recorded in an electronic database and included age, gender, dialysis vintage, cause of primary renal disease, diabetes mellitus status, body mass index (BMI), dates and microbiology of peritonitis episodes, and patient baseline assay results.

Peritonitis was diagnosed when at least two of the following are present: (1) clinical features consistent with peritonitis, i.e., abdominal pain and/or cloudy dialysate effluent; (2) dialysate effluent white cell count >100/μL or >0.1 × 10^9/L (after a dwell time of at least 2 h), with >50% polymorphonuclear; and (3) positive dialysate effluent culture.

**Measurement of biochemical parameters**

Serum albumin was determined by the bromcresol green method. Other biochemical indices, such as blood urea, serum creatinine, uric acid, serum potassium, total cholesterol, triglyceride, ferritin, highsensitivity C-reactive protein (hs-CRP) and parathyroid hormone (PTH), were determined using standard methods.

**Measurement of serum S1P**

S1P was analyzed by enzyme-linked immunosorbent assay (ELISA) using a commercial kit (Nordic BioSite AB, Sweden). The assay was conducted according to the manufacturer’s instructions. A 96-well plate was coated with S1P in advance and blocked to reduce nonspecific binding. After mixing the S1P standards and serum samples with the anti-S1P antibody, we added the mixture to the plate. The antibody competes for binding to S1P bound to the plate or in the serum sample. Following a 1-h incubation period and five washes of the plate, we added streptavidin–horseradish peroxidase (HRP) to the plate. After an additional incubation period, we added 3,30,5,50-tetramethylbenzidine (TMB) substrate. We stopped the reaction by adding sulfuric acid. We then measured the absorbance at 450 nm within 15 min. The concentration of S1P in the serum samples was determined by comparing values to those in a standard curve.

**Measurement of dialysis adequacy and residual renal function**

Residual renal function was measured as glomerular filtration rate (GFR) using the mean rate for urea and creatinine clearance [24]. The dialysis dose was measured according to the instilled dialysate volume. Small solute removal was determined by measurement of total (peritoneal dialysis and renal) weekly urea Kt/V using standard methods [25]. The contributions to total Kt/V (tKt/V) by peritoneal dialysis (pKt/V) and residual renal function (rKt/V) were estimated separately. The volume of urea distribution (V) was derived using Watson’s formula [26].

**Statistical analysis**

Continuous variables are expressed as means ± standard deviation for continuous normally distributed variables, and medians [interquartile range; IQR] for continuous variables that were not normally distributed; categorical variables are expressed as percentages. Peritonitis and non-peritonitis groups were compared using an independent t-test or Mann-Whitney’s test, depending on the data distribution. For comparison of categorical variables in two groups, such as the proportion of
diabetics or gender distribution, chi-square tests were employed. Logistic regression analysis was used to assess factors associated with peritonitis. The variables identified by univariable regression models \((p < 0.1)\) were further selected into the multivariable logistic regression model to determine whether they could independently affect peritonitis. Multivariable logistic regression analysis was used with the entry method. Results of the regression models are reported as odds ratio (OR) with 95% confidence interval (95% CI). All tests were two sided and \(p < 0.05\) was considered to be statistically significant. Statistical analysis was performed using SPSS software, version 25.0 (SPSS Inc., Chicago, Illinois, USA).

**Results**

**Demographic characteristics and clinical profile of the study population**

A total of 78 PD patients were included. During the follow-up, a total of 13 episodes of peritonitis were recorded. Gram negative, Gram positive and culture negative peritonitis occurred in 5, 3 and 5 patients, respectively. The culture of patients with Gram negative bacilli was all *Escherichia coli*. The culture of patients with Gram positive cocci were all coagulase-negative staphylococci. All the patients’ treatment protocol followed the 2016 ISPD guideline, with initial treatment of vancomycin and ceftazidime in our center. Patients were divided into two groups according to whether or not they had peritonitis during follow-up, resulting in a non-peritonitis \((n = 65)\) and peritonitis \((n = 13)\) group. The baseline comparisons between the two groups are described in Table 1. The time interval between laboratory tests and subsequent peritonitis was 10.2 (IQ 2.26, 10.62) months. Patients with peritonitis had a lower level of S1P than that of patients without peritonitis \((1.3 \text{ ng/mL} \text{ IQ 0.8, 3.6 ng/mL vs. 2.8 ng/mL IQ1.5, 5.4 ng/mL, } p = 0.018)\) (Figure 1). In addition, the peritonitis group had lower serum albumin \((34.4 \pm 4.7 \text{ g/L vs. 37.0} \pm 3.0 \text{ g/L, } p = 0.010)\), lower blood leukocyte \((6.2 \pm 1.2 \times 10^9/\text{L vs. 7.7} \pm 2.0 \times 10^9/\text{L, } p = 0.007)\), lower hemoglobin \((106.7 \pm 9.3 \text{ g/L vs. 115.1} \pm 11.0 \text{ g/L, } p = 0.012)\) and lower platelet count \((141.8 \pm 63.3 \times 10^12/\text{L vs. 204.8} \pm 67.4 \times 10^{12}/\text{L, } p = 0.003)\) as compared to the non-peritonitis group. There was no significant difference between the peritonitis and non-peritonitis patients with respect to the other variables.

**Logistic regression analysis**

Logistic regression analysis was performed to identify independent factors associated with peritonitis. The results of the logistic regression analysis are shown in Table 2. The following variables reached statistical significance: **Table 1. Clinical parameters at baseline for groups of peritonitis and non-peritonitis patients.**

| Variable                  | Non-peritonitis \(n = 65\) | Peritonitis \(n = 13\) | \(p\)-Value |
|---------------------------|----------------------------|------------------------|-------------|
| Gender (male)             | 50.8%                      | 53.8%                  | 1.000       |
| Age (years)               | 64.3 ± 11.6                | 65.3 ± 11.4            | 0.780       |
| Diabetes mellitus (%)     | 66.1%                      | 69.2%                  | 1.000       |
| BMI (kg/m²)               | 22.7 ± 3.7                 | 23.6 ± 3.6             | 0.977       |
| Dialysis vintage (years)  | 5.2 ± 3.5                  | 3.8 ± 2.9              | 0.176       |
| Previous peritonitis episode (%) | 29.2%            | 30.8%                  | 0.912       |
| Residual GFR (ml/min/1.73 m²) | 0 (0, 12.0)     | 0 (0, 7.9)             | 0.280       |
| Peritoneal Ccr (ml/min)   | 42.2 ± 9.3                 | 41.4 ± 9.5             | 0.777       |
| Residual Ccr (ml/min)     | 0 (0, 14.9)                | 0 (0, 16.9)            | 0.477       |
| Total Ccr (ml/min)        | 51.6 ± 14.2                | 48.2 ± 9.0             | 0.409       |
| Peritoneal Kt/V           | 1.7 ± 0.3                  | 1.6 ± 0.4              | 0.531       |
| Residual renal Kt/V       | 0 (0, 0.2)                 | 0 (0, 0.4)             | 0.685       |
| Total Kt/V                | 1.9 ± 0.4                  | 1.8 ± 0.3              | 0.524       |
| Instilled dialysate volume (L/day) | 8.6 ± 1.3        | 8.3 ± 1.5              | 0.398       |
| Serum S1P (ng/ml)         | 2.8 (1.5, 5.4)             | 1.3 (0.8, 3.6)         | 0.018       |
| Creatinine (µmol/L)       | 874 (763.5, 1012)          | 775 (696.5, 1086.5)    | 0.503       |
| Urea (mmol/L)             | 17.7 ± 4.6                 | 17.5 ± 3.3             | 0.488       |
| Uric acid (µmol/L)        | 383.3 (340.5, 445)         | 394 (364.5, 429.7)     | 0.673       |
| Albumin (g/L)             | 37.0 ± 3.0                 | 34.4 ± 4.7             | 0.010       |
| Leukocyte (x10^9/L)       | 7.7 ± 2.0                  | 6.2 ± 1.2              | 0.007       |
| Hemoglobin (g/L)          | 115.1 ± 11.0               | 106.7 ± 9.3            | 0.012       |
| Platelet (x10^12/L)       | 204.8 ± 67.4               | 141.8 ± 63.3           | 0.003       |
| Serum potassium (mmol/L)  | 4.3 ± 0.6                  | 4.3 ± 0.4              | 0.874       |
| Total cholesterol (mmol/L)| 4.9 ± 1.1                  | 4.3 ± 1.0              | 0.093       |
| Triglyceride (mmol/L)     | 2.7 ± 1.9                  | 1.7 ± 1.3              | 0.098       |
| PTH (pg/mL)               | 163.8 (65.1, 352.2)        | 147.1 (102.5, 253.6)   | 0.945       |
| Ferritin (ng/mL)          | 264 (187, 343)             | 248.6 (173, 361)       | 0.536       |
| hs-CRP (mg/L)             | 4.9 (1.6, 17.2)            | 3.1 (0.8, 7.7)         | 0.230       |

BMI: body mass index; Residual GFR: residual glomerular filtration rate; Ccr: creatinine clearance rate; S1P: sphingosine 1-phosphate; PTH: parathyroid hormone; hs-CRP: high-sensitivity C-reactive protein.
significance at a p-value of 0.1 or lower for the univariate logistic regression: S1P (OR = 0.652, 95% CI = 0.427–0.997, p = 0.048), leukocyte count (OR = 0.554, 95% CI = 0.348–0.882, p = 0.013), hemoglobin (OR = 0.928, 95% CI = 0.872–0.987, p = 0.017), platelet (OR = 0.982, 95% CI = 0.970–0.994, p = 0.004), serum albumin (OR = 0.806, 95% CI = 0.673–0.965, p = 0.019) and total cholesterol (OR = 0.595, 95% CI = 0.322–1.101, p = 0.098). The results of the multivariable logistic regression model showed that S1P (OR = 0.381, 95% CI = 0.171–0.848, p = 0.018), blood leukocyte count (OR = 0.438, 95% CI = 0.207–0.925, p = 0.030), and serum albumin (OR = 0.732, 95% CI = 0.556–0.962, p = 0.025) were independent factors associated with episode of peritonitis in the PD study population.

**Discussion**

In the present study, we found that patients with subsequent PD related peritonitis had significantly lower serum S1P levels than patients without peritonitis. Most importantly, the serum S1P level was a significant factor associated with peritonitis after adjusting for other confounding factors.

Peritonitis is still the major cause of patient technique failure and dropout from PD therapy. A number of established risk factors have been discovered to be associated with PD related peritonitis. Recently, much attention has been paid to the leak gut hypothesis [27]. Gastrointestinal problems, such as constipation and enteritis, have been reported to be associated with peritonitis due to enteric organisms in PD patients [28–30]. Our previous study has proved that gastrointestinal symptoms predict peritonitis rates in PD patients [30].

The mechanisms by which micro-organisms from the intestinal lumen gain access to the peritoneal cavity and cause enteric peritonitis may depend on the

![Figure 1. Sphingosine 1-phosphate level in patients with or without peritonitis during follow-up.](image)

![Table 2. Logistic regression analysis of the independent factors associated with peritonitis in PD patients.](table)
integrity of the intestinal wall, bacterial overgrowth status in the intestinal lumen and host peritoneal defense mechanisms [31,32]. Several observations have provided indirect evidence of intestinal barrier dysfunction in patients and animals with advanced chronic kidney disease [13]. Damage to the intestinal barrier and increased intestinal permeability may precede and promote translocation of bacteria and endotoxins [14,33]. Intestinal bacterial translocation in both chronic renal failure patients and experimental chronic renal failure models have been reported [34–36]. Studies also have shown that colon wall inflammation, along with destruction of the intestinal epithelial tight junction barrier, could lead to translocation of bacterial DNA and lipopolysaccharide into the bloodstream [34,37].

S1P is a bioactive lysophospholipid with important biological functions, which include cell adhesion, barrier regulation, migration, immune cell trafficking, proliferation and survival [16–22]. Many studies have reported that S1P protects intestinal epithelial cells, enhances the intestinal barrier function and ensures its integrity from apoptosis, proliferation, and migration by regulating the expression of adherens junction proteins [23,38–41]. A recent study has also showed that S1P signaling affects the migration of peritoneal B Cell populations and influences the production of intestinal IgA, suggesting that S1P signaling may be a target for modulating B cell function in inflammatory intestinal pathologies [42]. Therefore, the decreased S1P levels found in the present study may be an indicator for impaired intestinal barrier function and integrity, which facilitate the translocation of bacteria.

On the other hand, we found that serum S1P level was negatively associated with high-sensitivity C-reactive protein (hs-CRP) level \( (r = 0.61, \quad p < 0.001) \), which indicates that S1P may also be associated with systemic inflammation. A recent study displayed similar phenomena, showing that the serum S1P level dramatically decreased and was inversely associated with disease severity in patients with sepsis [43]. We speculated that the disruption of the intestinal barrier function and integrity by a decrease in S1P level not only promotes translocation of bacteria but also may increase the levels of endotoxins, uremic toxins and lipopolysaccharides, which can potentially contribute to local and systemic inflammation and malnutrition. As systemic inflammation and malnutrition are well-known risk factors for PD related peritonitis [44–46], these risk factors may have predisposed the patients in the present study with decreased S1P concentrations to peritonitis.

In the present study, baseline blood leukocyte count was found as a protective factor for the episode of peritonitis in the PD patients. As blood leukocyte level was considered as a general marker of immunocompetence [47], total blood leukocyte count might provide a representation of the immune response to peritonitis and play an important role in the inflammatory response in PD patients. However, components of leukocytes, such as neutrophils, lymphocytes and macrophages, which could represent the immunocompetence [48,49], were not collected in the study. Serum potassium level was not a risk factor for PD peritonitis, possibly because of the relatively small sample of only 8.9% patients who had hypokalemia.

Strengths of the present study included the availability of serum S1P in stable CAPD patients. To our knowledge, this was the first study to evaluate the association of serum S1P with subsequent peritonitis in PD patients.

There were some limitations in the present study. The major limitation of this study was its observational design. Therefore, the independent link between peritonitis and level of S1P cannot demonstrate cause and effect. Second, the time interval between S1P measurement and subsequent peritonitis was a relatively long time period. Third, the total number of CAPD patients and patients with peritonitis was relatively small. In addition, we did not collect data about using laxatives. Thus, it is not clear whether laxatives might contribute to the difference in S1P levels.

In conclusion, this study showed serum S1P was independently and negatively associated with peritonitis in PD patients. Serum S1P might serve as a biomarker to predict peritonitis in PD patients.

Acknowledgements
Qiong Bai was involved in the data collection, data analysis, and drafting of the manuscript. Chun-Yan Su was involved in data collection and analysis. Tao Wang was involved in interpretation of the results. Wen Tang conceptualized the study, interpreted the results and contributed to the writing of the draft.

Ethical approval
The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The study protocol has been approved by the Peking University Third Hospital Medical Science Research Ethics Committee on human research (IRB00006761-M2019218).

Disclosure statement
No potential conflict of interest was reported by the author(s).
Funding

This work was supported by grants from National Natural Science Foundation of China [Project 30900681], Chinese Society of Nephrology [No. 1405046058] and Fund of Peking University Health Science Center [BMU20160584]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

[1] Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13(2):90–103.
[2] Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508.
[3] Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis. 2014;64(2):278–289.
[4] Kumar VA, Sidell MA, Yang WT, et al. Predictors of peritonitis, hospital days, and technique survival for peritoneal dialysis patients in a managed care setting. Perit Dial Int. 2014;34(2):171–178.
[5] Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int. 2011;31(6):614–630.
[6] Aguirre Valadez JM, Rivera-Espinosa L, Mendez-Guerrero O, et al. Intestinal permeability in a patient with liver cirrhosis. Ther Clin Risk Manag. 2016;12:1729–1748.
[7] Chang CS, Yang SS, Kao CH, et al. Small intestinal bacterial overgrowth versus antimicrobial capacity in patients with spontaneous bacterial peritonitis. Scand J Gastroenterol. 2001;36(1):92–96.
[8] Hirako M, Kamiya T, Misu N, et al. Impaired gastric motility and its relationship to gastrointestinal symptoms in patients with chronic renal failure. J Gastroenterol. 2005;40(12):1116–1122.
[9] Strid H, Simren M, Stotzer PO, et al. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67(3):129–137.
[10] Stompor T, Hubalewska-Hola A, Staszczak A, et al. Association between gastric emptying rate and nutritional status in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int. 2002;22(4):500–505.
[11] Wang F, Jiang H, Shi K, et al. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton). 2012;17(8):733–738.
[12] Shi K, Wang F, Jiang H, et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci. 2014;59(9):2109–2117.
[13] Vaziri ND, Zhao YY, Pahl MV. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2016;31(5):737–746.
[14] Thalheimer U, De Iorio F, Capra F, et al. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol. 2010;22(10):1228–1234.
[15] Cereijido M, Shoshani L, Contreras RG. Molecular physiology and pathophysiology of tight junctions. I. Biogenesis of tight junctions and epithelial polarity. Am J Physiol Gastrointest Liver Physiol. 2000;279(3):G477–G482.
[16] Dudek SM, Jacobson JR, Chiang ET, et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem. 2004;279(23):24692–24700.
[17] English D, Kovala AT, Welch Z, et al. Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res. 1999;8(6):627–634.
[18] Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105(8):3178–3184.
[19] McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem. 2004;92(6):1075–1085.
[20] Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine 1-phosphate. Biochim Biophys Acta. 2002;1582(1-2):204–215.
[21] Singleton PA, Dudek SM, Chiang ET, et al. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. Faseb J. 2005;19(12):1646–1656.
[22] Singleton PA, Dudek SM, Ma SF, et al. Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem. 2006;281(45):34381–34393.
[23] Greenspon J, Li R, Xiao L, et al. Sphingosine-1-phosphate regulates the expression of adherens junction protein E-cadherin and enhances intestinal epithelial cell barrier function. Dig Dis Sci. 2011;56(5):1342–1353.
[24] van Olden RW, Krediet RT, Struijk DG, et al. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1996;7(5):745–750.
[25] Nolph KD, Moore HL, Prowant B, et al. Cross sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1993;13(3):178–183.
[26] Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33(1):27–39. The American Journal of Clinical Nutrition
[27] Salzer WL. Peritoneal dialysis-related peritonitis: challenges and solutions. Int J Nephrol Renovasc Dis. 2018;11:173–186.
Singharetnam W, Holley JL. Acute treatment of constipation may lead to transmural migration of bacteria resulting in gram-negative, polymicrobial, or fungal peritonitis. Perit Dial Int. 1996;16(4):423–425.

Wood CJ, Fleming V, Turnidge J, et al. Campylobacter peritonitis in continuous ambulatory peritoneal dialysis: report of eight cases and a review of the literature. Am J Kidney Dis. 1992;19(3):257–263.

Su CY, Pei J, Lu XH, et al. Gastrointestinal symptoms predict peritonitis rates in CAPD patients. CN. 2012;77(04):267–274.

Kosmadakis G, Albaret J, da Costa Correia E, et al. Gastrointestinal disorders in peritoneal dialysis patients. Am J Nephrol. 2018;48(5):319–325.

Yip T, Tse KC, Lam MF, et al. Colonic diverticulosis as a risk factor for peritonitis in Chinese peritoneal dialysis patients. Perit Dial Int. 2010;30(2):187–191.

Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34(1):32–37.

Wang F, Zhang P, Jiang H, et al. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci. 2012;57(11):2856–2862.

Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657–670.

March DS, Graham-Brown MP, Stover CM, et al. Intestinal barrier disturbances in haemodialysis patients: mechanisms, consequences, and therapeutic options. Biomed Res Int. 2017;2017:5765417.

Lau WL, Kalantar-Zadeh K, Vaziri ND. The gut as a source of inflammation in chronic kidney disease. Nephron. 2015;130(2):92–98.

Greenspon J, Li R, Xiao L, et al. Sphingosine-1-phosphate protects intestinal epithelial cells from apoptosis through the Akt signaling pathway. Dig Dis Sci. 2009;54(3):499–510.

Calise S, Blescia S, Cencetti F, et al. Sphingosine 1-phosphate stimulates proliferation and migration of satellite cells: role of S1P receptors. Biochim Biophys Acta. 2012;1823(2):439–450.

Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11(6):403–415.

Nagahashi M, Hait NC, Maceyka M, et al. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv Biol Regul. 2014;54:112–120.

Kleinwort A, Luhrs F, Heidecke CD, et al. S1P signalling differentially affects migration of peritoneal B cell populations in vitro and influences the production of intestinal IgA In Vivo. JMS. 2018;19(2):391.

Winkler M5, Nierhaus A, Holzmann M, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit Care. 2015;19(1):372.

Li PK, Ng JK, McIntyre CW. Inflammation and peritoneal dialysis. Semin Nephrol. 2017;37(1):54–65.

Huang JW, Lien YC, Wu HY, et al. Lean body mass predicts long-term survival in Chinese patients on peritoneal dialysis. PloS One. 2013;8(1):e54976.

Kerschbaum J, Konig P, Rudnicki M. Risk factors associated with peritoneal-dialysis-related peritonitis. Int J Nephrol. 2012;2012:483250.

Vargas E, Apewokin S, Madan R. Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection. Anaerobe. 2017;45:101–105.

Lang CL, Wang MH, Hung KY, et al. Altered molecular repertoire of immune system by renal dysfunction in the elderly: is prediction and targeted prevention in the horizon? Epma J. 2013;4(1):17.

Fuentes E, Fuentes M, Alarcon M, et al. Immune system dysfunction in the elderly. An Acad Bras Cienc. 2017;89(1):285–299.